Abstract
Sprague-Dawley rats received [14C]amifloxacin mesylate either orally or intravenously at 20 mg (base equivalent) per kg. Blood radioactivity peaked at 0.5 h after oral administration and was equivalent to 7.54 micrograms/ml for males and 6.73 micrograms/ml for females. After intravenous administration to rats, 52.5% of the dose was recovered in the urine of males and 45.3% in the urine of females within 72 h. The corresponding values after oral administration were 50.8% for males and 37.2% for females. The remainder of the dose was recovered in the feces. After intravenous administration of [14C]amifloxacin mesylate at 10 mg (base equivalent) per kg to female rhesus monkeys, 80.3% of the radioactivity was excreted in the urine at 24 h. The apparent first-order terminal elimination half-life of intact amifloxacin in plasma was 2.3 h; radioactivity in plasma was eliminated more slowly. Male rats excreted 26.2% of the dose in the urine as amifloxacin and 17.8% as the piperazinyl-N-oxide derivative of amifloxacin after intravenous administration. The corresponding amounts for female rats were 29.0% as amifloxacin and 7.8% as the piperazinyl-N-oxide metabolite. Similar excretion profiles were observed after oral administration. After intravenous administration, female monkeys excreted 54.5% of the dose in the urine as amifloxacin, 12.9% as the piperazinyl-N-desmethyl metabolite, and 5.6% as the piperazinyl-N-oxide during the first 12 h. In contrast, there was no evidence of the piperazinyl-N-desmethyl metabolite in rats.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benziger D. P., Edelson J. Disposition of arildone, an antiviral agent, after various routes of administration. Antimicrob Agents Chemother. 1982 Sep;22(3):475–481. doi: 10.1128/aac.22.3.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goueffon Y., Montay G., Roquet F., Pesson M. Sur un nouvel antibactérien de synthèse : l'acide éthyl-1 fluoro-6 (méthyl-4 pipérazinyl-1)-7 oxo-4 dihydro-1.4 quinoléine-3 carboxylique (1589 R.B.). C R Seances Acad Sci III. 1981 Jan 5;292(1):37–40. [PubMed] [Google Scholar]
- Izawa A., Yoshitake A., Komatsu T. Absorption and excretion of miloxacin in mice, rats, and dogs. Antimicrob Agents Chemother. 1980 Jul;18(1):41–44. doi: 10.1128/aac.18.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCoy L. F., Crawmer B. P., Benziger D. P. Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys. Antimicrob Agents Chemother. 1985 May;27(5):769–773. doi: 10.1128/aac.27.5.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Montay G., Blain Y., Roquet F., Le Hir A. High-performance liquid chromatography of pefloxacin and its main active metabolites in biological fluids. J Chromatogr. 1983 Feb 11;272(2):359–365. doi: 10.1016/s0378-4347(00)86139-3. [DOI] [PubMed] [Google Scholar]
- Montay G., Goueffon Y., Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463–472. doi: 10.1128/aac.25.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pohlod D. J., Saravolatz L. D. In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin. Antimicrob Agents Chemother. 1984 Mar;25(3):377–379. doi: 10.1128/aac.25.3.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wentland M. P., Bailey D. M., Cornett J. B., Dobson R. A., Powles R. G., Wagner R. B. Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships. J Med Chem. 1984 Sep;27(9):1103–1108. doi: 10.1021/jm00375a003. [DOI] [PubMed] [Google Scholar]